IN8bio Completes Dose Escalation In Phase 1 Trial Of INB-100, A Potential First-In-Class Gamma-Delta T Cell Therapy For The Treatment Of Leukemias, And Initiates Enrollment For The Phase 2 Trial Of INB-400 In Newly Diagnosed Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
IN8bio, Inc. (NASDAQ:INAB) has completed enrollment in the Phase 1 study of INB-100 in leukemia patients and initiated patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM). The company's CEO, William Ho, expressed optimism about the potential of gamma-delta T cells as a treatment option for both solid and hematological cancers. INB-400 was granted Orphan Drug Designation by the FDA in April 2023.
October 12, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IN8bio's completion of the Phase 1 trial of INB-100 and the initiation of the Phase 2 trial of INB-400 could potentially boost investor confidence in the company's innovative gamma-delta T cell therapies. The FDA's Orphan Drug Designation for INB-400 also adds credibility to the company's research and development efforts.
The completion of the Phase 1 trial of INB-100 and the initiation of the Phase 2 trial of INB-400 indicate that IN8bio is making progress in its research and development efforts. This could potentially attract more investors to the company. Additionally, the FDA's Orphan Drug Designation for INB-400 signifies that the drug has potential for treating a rare disease, which could further boost investor confidence in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100